Gen-Probe Inc. and Molecular Biosystems (NYSE:MB), both ofSan Diego, Calif., announced Monday they have settled theirpatent litigation concerning diagnostic test kits using geneticprobe technology.
In the settlement, Molecular Biosystems' wholly-ownedsubsidiary Syngene Inc. agreed that Gen-Probe's U.S. patent No.4,851,330 for targeting ribosomal RNA is valid. Syngene alsowill discontinue its SNAP mycobacterium diagnostic kits andpay Gen-Probe an undisclosed sum.
(c) 1997 American Health Consultants. All rights reserved.